Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Bolt Biotherapeutics

Bolt Biotherapeutics

Bolt Biotherapeutics is developing its novel BoltbodyTM platform, a cancer immunotherapy that consists of Immune-Stimulating Antibody Conjugates (ISAC).

Bolt Biotherapeutics is a biotechnology company in California that focuses on developing a platform for cancer immunotherapy. Founded 2015 in Redwood City, California, United States by CP Liu and Edgar Engleman, Bolt Biotherapeutics is a developer of bio-therapeutics designed to cure cancer models. The company's bio-therapeutic products enable physicians to treat various forms of cancer. Bolt Biotherapeutics is a platform consisting of systemically delivered Immune-Stimulating Antibody Conjugates (ISAC) called the Boltbody™ ISACS. These antibody conjugates reinvigorate the immune system and build an understanding of how dendritic and other myeloid cells generate effective anti-tumor immunity. These are immuno-oncology therapies that generate systemic immunological memory.

Timeline

July 1, 2020
Bolt Biotherapeutics raises a $93,500,000 series C round.
June 9, 2020
Bolt Biotherapeutics Announces Issuance of U.S. Patent for the BoltbodyTM ISAC Technology.

February 5, 2019
Bolt Biotherapeutics raises a $54,000,000 series B round.
February 2019
Bolt Biotherapeutics raises a $54,000,000 series B round from Nan Fung Life Sciences, Novo Holdings A/S, Pivotal bioVenture Partners and Vivo Capital.
2015
Founded

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Nick Paul
June 2, 2021
FierceBiotech
Genmab and Bolt Biotherapeutics have teamed up to develop bispecific immune-stimulating antibody conjugates. The collaboration brings together Genmab's bispecific capabilities with Bolt's innate immune stimulant platform to create a new type of immuno-oncology drug.
Ben Adams
February 5, 2021
FierceBiotech
As the biotech class of 2021 looks to outscore the deeply impressive turn it had last year, Bolt Biotherapeutics has raked in $230 million from its upsized IPO.
BioSpace
November 10, 2020
BioSpace
Bolt Biotherapeutics, a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, today presented the trial design of its ongoing Phase 1/2 clinical trial and preclinical data demonstrating proof-of-concept of its lead clinical drug candidate, BDC-1001.
Bolt Biotherapeutics, Inc.
November 10, 2020
www.prnewswire.com:443
/PRNewswire/ -- Bolt Biotherapeutics, a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and...
June 9, 2020
BioSpace
Bolt Biotherapeutics Announces Issuance of U.S. Patent for the BoltbodyTM ISAC Technology and its Lead Development Candidate, BDC-1001 - read this article along with other careers information, tips and advice on BioSpace
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.